Comparative Outcomes Between Direct Oral Anticoagulants, Warfarin, and Antiplatelet Monotherapy Among Chinese Patients w
- PDF / 1,307,925 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 16 Downloads / 169 Views
ORIGINAL RESEARCH ARTICLE
Comparative Outcomes Between Direct Oral Anticoagulants, Warfarin, and Antiplatelet Monotherapy Among Chinese Patients with Atrial Fibrillation: A Population‑Based Cohort Study Xue Li1,2,3,4 · Swathi Pathadka1 · Kenneth K. C. Man1,4,5 · Vanessa W. S. Ng1 · Chung Wah Siu6 · Ian C. K. Wong1,4,5 · Esther W. Chan1,4 · Wallis C. Y. Lau1,4,5
© Springer Nature Switzerland AG 2020
Abstract Introduction Outcomes associated with suboptimal use of antithrombotic treatments (antiplatelets, warfarin, direct oral anticoagulants [DOACs]) are unclear in Chinese patients with atrial fibrillation (AF). Objectives Our objective was to assess the prescription patterns, quality, effectiveness, and safety of antithrombotic treatments. Methods This was a population-based cohort study using electronic health records in Hong Kong. Patients newly diagnosed with AF during 2010–2016 were followed up until 2017. Patients at high stroke risk (CHA2DS2-VASc score ≥ 2) and receiving antithrombotic treatments were matched using propensity scoring. We used Cox proportional hazards regression to compare the risks of ischemic stroke, intracranial hemorrhage (ICH), gastrointestinal bleeding (GIB), and all-cause mortality between groups. Results Of the 52,178 high-risk patients with AF, 27,614 (52.9%) received antithrombotic treatment and were included in the analyses. Between 2010 and 2016, prescribing of antiplatelets and warfarin declined and that of DOACs increased dramatically (from 1 to 32%). Two-thirds of warfarin users experienced poor anticoagulation control. Warfarin and DOACs were associated with lower risks of ischemic stroke (warfarin, hazard ratio [HR] 0.51 [95% confidence interval (CI) 0.36–0.71]; DOACs, HR 0.69 [95% CI 0.51–0.94]) and all-cause mortality (warfarin, HR 0.47 [95% CI 0.39–0.57]; DOACs, HR 0.45 [95% CI 0.37–0.55]) than were antiplatelets. DOACs were associated with a lower risk of ICH than was warfarin (HR 0.53 [95% CI 0.34–0.83]). GIB risks were similar among all groups. Conclusion Antiplatelet prescribing and suboptimal warfarin management remain common in Chinese patients with AF at high risk of stroke. DOAC use may be associated with a lower risk of ischemic stroke and all-cause mortality when compared with antiplatelets and with a lower risk of ICH when compared with warfarin.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40264-020-00961-0) contains supplementary material, which is available to authorized users. * Wallis C. Y. Lau [email protected] Extended author information available on the last page of the article Vol.:(0123456789)
X. Li et al.
Key Points Since the introduction of the first direct oral anticoagulant (DOAC) in Hong Kong, the market share of DOACs has grown rapidly, from 1 to 32% between 2010 and 2016. Among patients newly diagnosed with atrial fibrillation (AF) in 2016, 43% had a high risk of ischemic stroke and received single antiplatelet therapy, against current guideline recommendations. Compared with
Data Loading...
